Evidence map›Paper›PMID 41219701›Full record

ArticleBMC microbiology2025

YZ462 exhibits potent antibacterial activity against methicillin-resistant Staphylococcus aureus through bacterial membrane disruption.

Weikai Guo, Yanyang Zhao, Yuqing Yang, Wenyu Li, Kexiao Wang, Fang Zhou, Jiaqi Li, Xiangfeng Li, Yuan Zhang, Biao Hu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weikai Guo *Henan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Yanyang Zhao *Henan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Yuqing Yang *Henan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Wenyu LiHenan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Kexiao WangHenan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Fang ZhouDepartment of Microbiology, College of Basic Medical Sciences, Henan University, Kaifeng, 475000, China.
Jiaqi LiHenan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Xiangfeng LiHenan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Yuan ZhangDepartment of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou, 450000, China.
Biao HuDepartment of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou, 450000, China.
Wenwen ZhangDepartment of Microbiology, College of Basic Medical Sciences, Henan University, Kaifeng, 475000, China.
Xin WeiThe Jointed National Laboratory of Antibody Drug Engineering, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Qiming LiHenan Province EngineeringTechnology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, the First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, China. liqiming82@126.com.

Funding

Kaifeng Science and Technology Development Program Projects 2303007Natural Science Foundation of Henan 232300420184Provinces and ministries jointly building key projects of the Henan Provincial Health Commission SBGJ202402084the Henan Province Key Research and Development and Promotion Project 242102310023; 252102310431The Key Scientific Research Projects of Colleges and Universities in Henan Province 25A350010
6 · The paper itself

Abstract

backgroundThe global rise of antibiotic resistance presents a critical public health challenge, with Staphylococcus aureus being a leading cause of hospital- and community-acquired infections. Methicillin-resistant S. aureus (MRSA) is particularly concerning due to its high prevalence, multidrug resistance, and association with severe morbidity and mortality. Developing novel small-molecule antimicrobial agents with reduced resistance susceptibility is essential to combat these infections.

resultsFrom our in-house compound library, we identified YZ462, a heteroaromatic-aryl scaffold compound, demonstrating potent antibacterial activity and low toxicity. YZ462 showed strong anti-MRSA effects through bacterial membrane disruption, increased permeability, and induction of endogenous ROS production. In vitro, it effectively killed both log-phase and stationary-phase MRSA while inhibiting biofilm formation and disrupting established biofilms. In vivo studies revealed significant reduction of bacterial loads and improved survival rates in infected animal models. Importantly, the major S. aureus membrane component cardiolipin (CL) directly interacted with YZ462 and attenuated its antibacterial activity, suggesting CL as a potential molecular target.

conclusionsOur study establishes YZ462 as a promising small-molecule candidate for MRSA treatment, featuring a unique mechanism of membrane disruption and ROS induction. These results confirm its potent antimicrobial activity and demonstrate therapeutic potential against MRSA infections.

Indexed as

Anti-Bacterial AgentsCell MembraneMethicillin-Resistant Staphylococcus aureusAnimalsBiofilmsCardiolipinsMiceMicrobial Sensitivity TestsReactive Oxygen SpeciesStaphylococcal InfectionsAnti-Bacterial AgentsCardiolipinsReactive Oxygen SpeciesAntimicrobial agentsBacterial infectionGram-positive pathogenMRSAYZ462

Identifiers

PMID41219701
PMCPMC12606902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.